PHAXIAM Therapeutics S.A. Long Term Debt

PHAXIAM Therapeutics S.A. (PHXM) currently reports a long-term debt of $7M as of December 2023. That compares with $10M in the prior-year period — down 31.3% year over year. Use the charts on this page to explore PHAXIAM Therapeutics S.A.'s long-term debt history and peer comparisons.

PHAXIAM Therapeutics S.A.'s long-term debt decreased from $10M to $7M — a 31.3% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PHAXIAM Therapeutics S.A. reported $7M in long-term debt as of December 2023. That compares with $10M in the prior-year period — down 31.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PHAXIAM Therapeutics S.A., and consider following PHXM for alerts when major investors trade the stock.

PHAXIAM Therapeutics S.A. is classified in the Healthcare sector. On long-term debt, it currently shows $7M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHXM with unrelated industries.